Insights & Resources – COD Research – Designing Therapies For Future

The Evolution of PRO Collection: From Paper Diaries to ePRO Systems

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Biometrics

Clinical Services

CT Quality Assurance

Medical Affairs

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

Strategic Planning for Patient Recruitment

EMA
FDA
MHRA

Summary of the Medicine Shortages SPOC Working Party meeting on 17 June 2025
Source: EMA Published on 2025-07-29
Nitrosamine impurities
Source: EMA Published on 2025-07-29
Report: European medicines regulatory network’s response to nitrosamine impurities in human medicines
Source: EMA Published on 2025-07-29
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Date of authorisation: 26/05/2025, Status: Authorised
Source: EMA Published on 2025-07-28
Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 10, Status: Authorised
Source: EMA Published on 2025-07-28
Human medicines European public assessment report (EPAR): Jubereq, denosumab, Date of authorisation: 26/05/2025, Status: Authorised
Source: EMA Published on 2025-07-28

Read More